LLY · News · 20260914N

Supply chain / counterfeit risk

ELI LILLY & Co · 2026-09-14 · Importance 31 · Surprise 42

Bootleg versions of an unapproved Lilly experimental weight-loss drug are reportedly circulating in the market. Ohio regulators are attempting to stop the supply of these unauthorized products. The activity indicates demand is exceeding authorized availability for the experimental obesity treatment and creates counterfeit, patient-safety and channel-control risks for Lilly.